Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 380 participants.

Also called NCT01177384

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 380 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01177384
  • CTRI CTRI/2011/10/002072
Other papers using this trial's data
  • A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone Current medical research and opinion, 2017-04 DOI, PubMed 28035868

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01177384. Randomized; double masking; primary purpose treatment. Start 2011-01-25 (actual); primary completion 2013-03-25 (actual). Results posted on 2014-04-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin phosphate
Intervention (Drug)
Comparator: Placebo
Intervention (Drug)
Acarbose
Intervention (Drug)
Glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01177384
Content hash
6546e44afde82fd3d20adedaccedf9f2fe82a73503fa9b9833f27e83fcaee4a5